Zongertinib to Target HER2-Driven Resistance in EGFR Mutation-Positive NSCLC: A Case Report.

Hernexeos (zongertinib) - Boehringer Ingelheim

http://www.ncbi.nlm.nih.gov/pubmed/42753421

Ana López-Martín; Cristina Serrano-Gómez; Helena Bote de Cabo; Javier Baena-Espinar; Javier Torres-Jiménez; Jon Zugazagoitia; Luis Paz-Ares; María Zurera-Berjaga; Santiago Ponce-Aix

Sep 18, 2026